Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and...
Coronary heart disease (CHD) often coexists with mood disorders (MDs), but research on comorbidity predictors and interventions remains limited. This two‑phase mixed‑methods study enrolled 390 CHD patients diagnosed by coronary angiography. Mood disorders were screened using the HAMD (≥7) and confirmed via DSM‑5 psychiatric evaluation. In the observational phase, 219 CHD patients with MDs and...
BACKGROUND: Hmong people experience a disproportionate burden of mental health challenges. While prior studies have examined mental health within Hmong communities, no study has focused on Hmong shamans’ experiences with depression. This study explores how Hmong shamans understand, experience, and respond to depression. METHODS: We conducted semi-structured, in-depth interviews with 12 Hmong...
This study aims to explore the effectiveness of implementing BAKU (Good and Strong) culture in Islamic mindfulness therapy as an alternative treatment for anxiety and depression among young Muslims, particularly in the Daarut Tauhiid Bandung environment. The background of this study is based on the high prevalence of mental health disorders, such as anxiety and depression, among Indonesian...
Background: Anhedonia and reward-processing deficits are core features of major depressive disorder (MDD) that respond poorly to traditional antidepressants.Ketamine has rapid antidepressant effects, yet its neurofunctional actions within reward circuits remain unclear.We synthesized human neuroimaging evidence on ketamine-related modulation of reward circuitry and implications for...
Abstract New treatments for depression are needed that combine robust efficacy with improved scalability. Although psilocybin has demonstrated antidepressant effects in Phase 3 clinical trials, some of its psychedelic effects limit tolerability, necessitating administration in highly supervised clinical settings, and thus motivating development of serotonergic therapeutics that preserve...
Upwards of 50% of people do not respond to the primary treatment modalities for major depressive disorder (MDD), which has led to increased attention and use of alternative methods, including exercise and psychedelics. While interventions using either exercise or psychedelics have demonstrated largely positive results in isolation, their synergistic potential has yet to be explored. As such,...
Intranasal esketamine represents a novel therapeutic option for Treatment-Resistant Depression (TRD). However, its medium-to-long-term risk-benefit profile in real-world clinical practice remains controversial. Limited data is available regarding its effectiveness, particularly in patients who have not responded to electroconvulsive therapy (ECT), which is the focus of this study. We conducted...
Treatment-resistant depression (TRD) accounts for approximately 30% of major depressive disorder cases and has been characterized by altered functional connectivity within and between the Default Mode (DMN) and Frontoparietal networks (FPN). Ketamine can be an effective treatment for TRD, and its antidepressant response has been associated with alterations in resting state functional...
Postoperative depression adversely influences breast cancer patients' clinical outcomes. Our prior study demonstrated that intraoperative esketamine ameliorated postoperative depression in breast cancer patients, yet the underlying neural mechanism remains incompletely understood. We performed a double-blind randomized controlled trial in 35 breast cancer patients with preoperative depressive...
Stress and HealthMarch 5, 2026A. G. Little, Matthew J. Stainer, Alex Sandy MacQuarrie et al.1 citation
Paramedicine students experience disproportionately high rates of anxiety, depression, stress, and insomnia compared to the general population, placing them at risk of post-traumatic stress disorder and long-term psychological distress. Breathwork has emerged as a promising self-regulation intervention that may enhance resilience and wellbeing while reducing symptoms of mental illness. This...
Approximately 30% of patients with depression suffer from treatment-resistant depression (TRD). Ketamine has shown antidepressant efficacy for TRD. While glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) has been demonstrated to play crucial roles in the process of pharmacological action of ketamine in experimental animals, it remains elusive how ketamine exhibits...
Background Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharmacotherapies often provide delayed or incomplete relief and may increase the risk of treatment-emergent affective switching. Recent evidence highlights the therapeutic potential of NMDA receptor antagonists, particularly ketamine and its S-enantiomer...
Introduction: This study examined the pathways linking mindfulness to emotion regulation and psychological symptoms among adults in Saudi Arabia. Methods: A total of 306 adults completed validated measures of mindfulness, emotion regulation (cognitive reappraisal and expressive suppression), depression, and anxiety. Structural equation modeling was used to test a hypothesized model in which...
Ketamine is a powerful and rapid-acting antidepressant but has no regulatory authorization for any psychiatric illness. The S-enantiomer of ketamine, esketamine, was approved by the FDA in 2019 as adjunctive therapy for treatment-resistant depression. Substantial controversy exists as to whether there is a significant clinical difference between intravenous (IV) ketamine racemate and intranasal...
Cannabis use is associated with psychiatric comorbidities, and the use of elta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Observational data were drawn from three years of the nationally...
PURPOSE: Increased depression, anxiety and stress symptoms are associated with reduced mindfulness levels and coping skills. This study primarily aimed to investigate (1) the relationships between mindfulness, coping styles, depression, anxiety and stress and (2) mindfulness and coping styles as predictors of depression, anxiety and stress in adults who stutter. A secondary aim was to compare...
Online Mindfulness-Based Cognitive Therapy (MBCT) is a promising intervention for mental health, but its effectiveness in reducing depressive symptoms remains underexplored. While key mechanisms of change have been identified in traditional MBCT, their role in online delivery formats needs further investigation. This study aimed to evaluate the effectiveness of synchronous and asynchronous...
Electroconvulsive therapy (ECT) has long been considered the main method of treatment for patients with resistant major depressive disorder (MDD). Recent studies have shown that ketamine infusion can also effectively improve treatment-resistant MDD. Thus, we conducted this meta-analysis to compare the efficacy of ketamine with ECT for treating treatment-resistant depression. We systematically...
Major depressive disorder (MDD) is increasingly viewed as a disorder of impaired neural plasticity, yet the mechanisms underlying diverse antidepressant classes - glutamatergic (e.g., ketamine), monoaminergic (e.g., selective serotonin reuptake inhibitors (SSRIs)), and GABAergic (e.g., neurosteroids) - remain incompletely integrated. The objective of this study was to extend a...